Nitroreductase (NTR) (NTR)

Nitroreductases (NTRs) are a diverse family of enzymes, primarily found in bacteria and some eukaryotes, that catalyze the reduction of nitroaromatic compounds using NAD(P)H as an electron donor (Wikipedia). In modern pharmacology, NTRs are the cornerstone of Gene-Directed Enzyme Prodrug Therapy (GDEPT), where a bacterial NTR gene (such as E. coli nfsB) is delivered to tumor cells to convert non-toxic prodrugs into highly potent cytotoxic metabolites (Ackerley Lab). This localized activation allows for high concentrations of DNA-damaging agents within the tumor microenvironment while minimizing systemic exposure and side effects (Li et al., 2024). Beyond oncology, NTRs are the primary targets for several antimicrobial agents, including metronidazole and nitrofurantoin, which are activated by endogenous bacterial NTRs to exert their bactericidal effects (PubChem). The enzyme's unique ability to chemically transform nitro groups makes it a valuable tool for cell ablation studies, diagnostic imaging of hypoxia, and environmental bioremediation (AAT Bioquest). The efficacy of NTR-based therapies depends on the specific substrate-enzyme pairing and the efficient delivery of the enzyme to the target tissue. However, challenges such as the immunogenicity of bacterial enzymes and off-target activation by the gut microbiome remain significant hurdles in clinical development.

Other names

Oxygen-insensitive NAD(P)H nitroreductasenfsBnfsANitrobenzene nitroreductaseDihydropteridine reductaseNitroreductase family

Nitroreductases catalyze the NAD(P)H-dependent reduction of nitro groups on prodrugs to form cytotoxic hydroxylamines or amines, which typically act as DNA cross-linking agents or induce oxidative stress (Ackerley Lab; Wikipedia).